251
|
Sun M, Huang F, Yu D, Zhang Y, Xu H, Zhang L, Li L, Dong L, Guo L, Wang S. Autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK pathway in rhabdomyosarcoma modulates proliferation and differentiation. Cell Death Dis 2015; 6:e1859. [PMID: 26291313 PMCID: PMC4558514 DOI: 10.1038/cddis.2015.225] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2014] [Revised: 05/13/2015] [Accepted: 07/07/2015] [Indexed: 12/30/2022]
Abstract
The origin of rhabdomyosarcoma (RMS) remains controversial. However, specific microRNAs (miRNAs) are downregulated in RMS and it is possible that re-expression of these miRNAs may lead to differentiation. Transforming growth factor-β1 (TGF-β1) is known to block differentiation of RMS. We therefore analyzed miRNA microarrays of RMS cell lines with or without TGF-β1 knockdown and identified a novel anti-oncogene miR-411-5p. Re-expression of miR-411-5p inhibited RMS cell proliferation in vitro and tumorigenicity in vivo. Using a luciferase reporting system and sequence analysis, the potential target of miR-411-5p was identified as sprouty homolog 4 (SPRY4), which inhibits protein kinase Cα-mediated activation of mitogen-activated protein kinases (MAPKs), especially p38MAPK phosphorylation. These results revealed an inverse correlation between TGF-β1/SPRY4 and miR-411-5p levels. SPRY4 small interfering RNA and miR-411-5p both activated p38MAPK phosphorylation and also promoted apoptosis and myogenic differentiation, indicated by increased caspase-3, myosin heavy chain, and myosin expression. SPRY4 and miR-411 mRNA levels correlated with TGF-β1 expression levels in RMS tissues, which was confirmed by immunohistochemical staining for TGF-β1, SPRY4, and phosphorylated p38MAPK proteins. Overall, these results indicate that miR-411-5p acts as an RMS differentiation-inducing miRNA prompting p38MAPK activation via directly downregulating SPRY4. These results establish an autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK in RMS, which governs the switch between proliferation and differentiation.
Collapse
|
252
|
Romero-Nava R, Rodriguez JE, Reséndiz-Albor AA, Sánchez-Muñoz F, Ruiz-Hernandéz A, Huang F, Hong E, Villafaña S. Changes in protein and gene expression of angiotensin II receptors (AT1 and AT2) in aorta of diabetic and hypertensive rats. Clin Exp Hypertens 2015; 38:56-62. [PMID: 26268856 DOI: 10.3109/10641963.2015.1060984] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
Diabetes and hypertension have been associated with cardiovascular diseases and stroke. Some reports have related the coexistence of hypertension and diabetes with increase in the risk of developing vascular complications. Recently some studies have shown results suggesting that in the early stages of diabetes and hypertension exist a reduced functional response to vasopressor agents like angiotensin II (Ang II), which plays an important role in blood pressure regulation mechanism through the activation of its AT1 and AT2 receptors. For that reason, the aim of this work was to study the gene and protein expression of AT1 and AT2 receptors in aorta of diabetic SHR and WKY rats. Diabetes was induced by the administration of streptozotocin (60 mg/kg i.p.). After 4 weeks of the onset of diabetes, the protein expression was obtained by western blot and the mRNA expression by RT-PCR. Our results showed that the hypertensive rats have a higher mRNA and protein expression of AT1 receptors than normotensive rats while the AT2 expression remained unchanged. On the other hand, the combination of diabetes and hypertension increased the mRNA and protein expression of AT1 and AT2 receptors significantly. In conclusion, our results suggest that diabetes with hypertension modifies the mRNA and protein expression of AT1 and AT2 receptors. However, the overexpression of AT2 could be associated with the reduction in the response to Ang II in the early stage of diabetes.
Collapse
|
253
|
Huang F, Ahmad W, Duan M, Liu Z, Guan Z, Zhang M, Qiao B, Li Y, Song Y, Song Y, Chen Y, Amjad Ali M. Efficiency of live attenuated and inactivated rabies viruses in prophylactic and post exposure vaccination against the street virus strain. Acta Virol 2015; 59:117-24. [PMID: 26104328 DOI: 10.4149/av_2015_02_117] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Rabies remains an enigmatic and widely discussed global infectious disease and causes an increasing number of deaths. The currently used highly effective prophylactic and post exposure (p.e.) vaccination depends solely upon inexpensive, effective and safe vaccines to counteract the spread of the disease. In this study, the potential of an attenuated Chinese rabies vaccine (SRV9) strain in prophylactic and p.e. vaccination against the street strain of rabies virus (RV) was evaluated in mice. Prophylactic vaccination consisting of one intramuscular (i.m.) dose of SRV9 protected 100% of mice from intracerebral (i.c.) challenge with a lethal dose of the street virus. The latter was detected in the brain of mice at day 6 post challenge by RT-PCR. Post exposure vaccination was performed at days 1, 2, 3, 4, 5 and 6 post infection (p.i.) with either SRV9 or inactivated rabies vaccine. The survival rates after i.m. inoculation of SRV9 at the indicated days were 70%, 50%, 30%, 20%, 10%, and 0%, respectively; the corresponding survival rates for the inactivated rabies vaccine were 30%, 20%, 10%, 0%, 0%, and 0%, respectively. However, 100%, 90%, 70%, 50%, 20%, 10%, and 10% of mice survived after i.c. inoculation of SRV9 at the indicated days. The increased permeability of the blood-brain barrier and the infiltration of CD19+ B cells into the central nervous system after i.c. inoculation of SRV9 are regarded as prerequisites for the clearance of the street virus. The obtained data suggest that SRV9 is a promising candidate for prophylactic and p.e. vaccination against rabies infection and that it exhibits a potential for the control of rabies in China.
Collapse
|
254
|
Aartsen MG, Abraham K, Ackermann M, Adams J, Aguilar JA, Ahlers M, Ahrens M, Altmann D, Anderson T, Archinger M, Arguelles C, Arlen TC, Auffenberg J, Bai X, Barwick SW, Baum V, Bay R, Beatty JJ, Tjus JB, Becker KH, Beiser E, BenZvi S, Berghaus P, Berley D, Bernardini E, Bernhard A, Besson DZ, Binder G, Bindig D, Bissok M, Blaufuss E, Blumenthal J, Boersma DJ, Bohm C, Börner M, Bos F, Bose D, Böser S, Botner O, Braun J, Brayeur L, Bretz HP, Brown AM, Buzinsky N, Casey J, Casier M, Cheung E, Chirkin D, Christov A, Christy B, Clark K, Classen L, Coenders S, Cowen DF, Silva AHC, Daughhetee J, Davis JC, Day M, André JPAMD, Clercq CD, Dembinski H, Ridder SD, Desiati P, Vries KDD, Wasseige GD, With MD, DeYoung T, Díaz-Vélez JC, Dumm JP, Dunkman M, Eagan R, Eberhardt B, Ehrhardt T, Eichmann B, Euler S, Evenson PA, Fadiran O, Fahey S, Fazely AR, Fedynitch A, Feintzeig J, Felde J, Filimonov K, Finley C, Fischer-Wasels T, Flis S, Fuchs T, Gaisser TK, Gaior R, Gallagher J, Gerhardt L, Ghorbani K, Gier D, Gladstone L, Glagla M, Glüsenkamp T, Goldschmidt A, Golup G, Gonzalez JG, Goodman JA, Góra D, Grant D, Gretskov P, Groh JC, Gross A, Ha C, Haack C, Ismail AH, Hallgren A, Halzen F, Hansmann B, Hanson K, Hebecker D, Heereman D, Helbing K, Hellauer R, Hellwig D, Hickford S, Hignight J, Hill GC, Hoffman KD, Hoffmann R, Holzapfel K, Homeier A, Hoshina K, Huang F, Huber M, Huelsnitz W, Hulth PO, Hultqvist K, In S, Ishihara A, Jacobi E, Japaridze GS, Jero K, Jurkovic M, Kaminsky B, Kappes A, Karg T, Karle A, Kauer M, Keivani A, Kelley JL, Kemp J, Kheirandish A, Kiryluk J, Kläs J, Klein SR, Kohnen G, Kolanoski H, Konietz R, Koob A, Köpke L, Kopper C, Kopper S, Koskinen DJ, Kowalski M, Krings K, Kroll G, Kroll M, Kunnen J, Kurahashi N, Kuwabara T, Labare M, Lanfranchi JL, Larson MJ, Lesiak-Bzdak M, Leuermann M, Leuner J, Lünemann J, Madsen J, Maggi G, Mahn KBM, Maruyama R, Mase K, Matis HS, Maunu R, McNally F, Meagher K, Medici M, Meli A, Menne T, Merino G, Meures T, Miarecki S, Middell E, Middlemas E, Miller J, Mohrmann L, Montaruli T, Morse R, Nahnhauer R, Naumann U, Niederhausen H, Nowicki SC, Nygren DR, Obertacke A, Olivas A, Omairat A, O’Murchadha A, Palczewski T, Paul L, Pepper JA, Heros CPDL, Pfendner C, Pieloth D, Pinat E, Posselt J, Price PB, Przybylski GT, Pütz J, Quinnan M, Rädel L, Rameez M, Rawlins K, Redl P, Reimann R, Relich M, Resconi E, Rhode W, Richman M, Richter S, Riedel B, Robertson S, Rongen M, Rott C, Ruhe T, Ruzybayev B, Ryckbosch D, Saba SM, Sabbatini L, Sander HG, Sandrock A, Sandroos J, Sarkar S, Schatto K, Scheriau F, Schimp M, Schmidt T, Schmitz M, Schoenen S, Schöneberg S, Schönwald A, Schukraft A, Schulte L, Seckel D, Seunarine S, Shanidze R, Smith MWE, Soldin D, Spiczak GM, Spiering C, Stahlberg M, Stamatikos M, Stanev T, Stanisha NA, Stasik A, Stezelberger T, Stokstad RG, Stössl A, Strahler EA, Ström R, Strotjohann NL, Sullivan GW, Sutherland M, Taavola H, Taboada I, Ter-Antonyan S, Terliuk A, Tešić G, Tilav S, Toale PA, Tobin MN, Tosi D, Tselengidou M, Unger E, Usner M, Vallecorsa S, Vandenbroucke J, Eijndhoven NV, Vanheule S, Santen JV, Veenkamp J, Vehring M, Voge M, Vraeghe M, Walck C, Wallace A, Wallraff M, Wandkowsky N, Weaver C, Wendt C, Westerhoff S, Whelan BJ, Whitehorn N, Wichary C, Wiebe K, Wiebusch CH, Wille L, Williams DR, Wissing H, Wolf M, Wood TR, Woschnagg K, Xu DL, Xu XW, Xu Y, Yanez JP, Yodh G, Yoshida S, Zarzhitsky P, Zoll M. A COMBINED MAXIMUM-LIKELIHOOD ANALYSIS OF THE HIGH-ENERGY ASTROPHYSICAL NEUTRINO FLUX MEASURED WITH ICECUBE. ACTA ACUST UNITED AC 2015. [DOI: 10.1088/0004-637x/809/1/98] [Citation(s) in RCA: 288] [Impact Index Per Article: 32.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
255
|
Deng YP, Zhao T, Huang F, Ni M, Li DJ, Jiang GJ, Shen FM. Fenofibrate Improves the Impaired Endothelial Progenitor Cell Function Through Deregulating Nalp3 Inflammasome Activity In Diabetic Mice. Clin Ther 2015. [DOI: 10.1016/j.clinthera.2015.05.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
256
|
Aartsen M, Ackermann M, Adams J, Aguilar J, Ahlers M, Ahrens M, Altmann D, Anderson T, Archinger M, Arguelles C, Arlen T, Auffenberg J, Bai X, Barwick S, Baum V, Bay R, Beatty J, Becker Tjus J, Becker KH, Beiser E, BenZvi S, Berghaus P, Berley D, Bernardini E, Bernhard A, Besson D, Binder G, Bindig D, Bissok M, Blaufuss E, Blumenthal J, Boersma D, Bohm C, Börner M, Bos F, Bose D, Böser S, Botner O, Braun J, Brayeur L, Bretz HP, Brown A, Buzinsky N, Casey J, Casier M, Cheung E, Chirkin D, Christov A, Christy B, Clark K, Classen L, Coenders S, Cowen D, Cruz Silva A, Daughhetee J, Davis J, Day M, de André J, De Clercq C, Dembinski H, De Ridder S, Desiati P, de Vries K, de Wasseige G, de With M, DeYoung T, Díaz-Vélez J, Dumm J, Dunkman M, Eagan R, Eberhardt B, Ehrhardt T, Eichmann B, Euler S, Evenson P, Fadiran O, Fahey S, Fazely A, Fedynitch A, Feintzeig J, Felde J, Filimonov K, Finley C, Fischer-Wasels T, Flis S, Fuchs T, Glagla M, Gaisser T, Gaior R, Gallagher J, Gerhardt L, Ghorbani K, Gier D, Gladstone L, Glüsenkamp T, Goldschmidt A, Golup G, Gonzalez J, Goodman J, Góra D, Grant D, Gretskov P, Groh J, Groß A, Ha C, Haack C, Haj Ismail A, Hallgren A, Halzen F, Hansmann B, Hanson K, Hebecker D, Heereman D, Helbing K, Hellauer R, Hellwig D, Hickford S, Hignight J, Hill G, Hoffman K, Hoffmann R, Homeier A, Hoshina K, Huang F, Huber M, Huelsnitz W, Hulth P, Hultqvist K, In S, Ishihara A, Jacobi E, Japaridze G, Jero K, Jurkovic M, Kaminsky B, Kappes A, Karg T, Karle A, Kauer M, Keivani A, Kelley J, Kemp J, Kheirandish A, Kiryluk J, Kläs J, Klein S, Kohnen G, Kolanoski H, Konietz R, Koob A, Köpke L, Kopper C, Kopper S, Koskinen D, Kowalski M, Krings K, Kroll G, Kroll M, Kunnen J, Kurahashi N, Kuwabara T, Labare M, Lanfranchi J, Larson M, Lesiak-Bzdak M, Leuermann M, Leuner J, Lünemann J, Madsen J, Maggi G, Mahn K, Maruyama R, Mase K, Matis H, Maunu R, McNally F, Meagher K, Medici M, Meli A, Menne T, Merino G, Meures T, Miarecki S, Middell E, Middlemas E, Miller J, Mohrmann L, Montaruli T, Morse R, Nahnhauer R, Naumann U, Niederhausen H, Nowicki S, Nygren D, Obertacke A, Olivas A, Omairat A, O’Murchadha A, Palczewski T, Paul L, Pepper J, Pérez de los Heros C, Pfendner C, Pieloth D, Pinat E, Posselt J, Price P, Przybylski G, Pütz J, Quinnan M, Rädel L, Rameez M, Rawlins K, Redl P, Reimann R, Relich M, Resconi E, Rhode W, Richman M, Richter S, Riedel B, Robertson S, Rongen M, Rott C, Ruhe T, Ruzybayev B, Ryckbosch D, Saba S, Sabbatini L, Sander HG, Sandrock A, Sandroos J, Sarkar S, Schatto K, Scheriau F, Schimp M, Schmidt T, Schmitz M, Schoenen S, Schöneberg S, Schönwald A, Schukraft A, Schulte L, Schulz O, Seckel D, Sestayo Y, Seunarine S, Shanidze R, Smith M, Soldin D, Spiczak G, Spiering C, Stahlberg M, Stamatikos M, Stanev T, Stanisha N, Stasik A, Stezelberger T, Stokstad R, Stößl A, Strahler E, Ström R, Strotjohann N, Sullivan G, Sutherland M, Taavola H, Taboada I, Ter-Antonyan S, Terliuk A, Tešić G, Tilav S, Toale P, Tobin M, Tosi D, Tselengidou M, Unger E, Usner M, Vallecorsa S, van Eijndhoven N, Vandenbroucke J, van Santen J, Vanheule S, Vehring M, Voge M, Vraeghe M, Walck C, Wallraff M, Wandkowsky N, Weaver C, Wendt C, Westerhoff S, Whelan B, Whitehorn N, Wichary C, Wiebe K, Wiebusch C, Wille L, Williams D, Wissing H, Wolf M, Wood T, Woschnagg K, Xu D, Xu X, Xu Y, Yanez J, Yodh G, Yoshida S, Zarzhitsky P, Zoll M. Measurement of the AtmosphericνeSpectrum with IceCube. Int J Clin Exp Med 2015. [DOI: 10.1103/physrevd.91.122004] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
257
|
Xu G, Ji C, Song G, Zhao C, Shi C, Song L, Chen L, Yang L, Huang F, Pang L, Zhang N, Zhao Y, Guo X. MiR-26b modulates insulin sensitivity in adipocytes by interrupting the PTEN/PI3K/AKT pathway. Int J Obes (Lond) 2015; 39:1523-30. [PMID: 25999046 DOI: 10.1038/ijo.2015.95] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2014] [Revised: 05/06/2015] [Accepted: 05/17/2015] [Indexed: 01/14/2023]
Abstract
BACKGROUND MicroRNAs (miRNAs) have emerged as epigenetic regulators of metabolism and energy homeostasis. There is a growing body of evidence pointing to miRNAs that have important regulatory roles in insulin sensitivity. OBJECTIVE The aim of this work was to explore the expression and mechanism of action of miR-26b in obesity-related insulin resistance (IR) in adipocytes. METHODS Quantitative real-time PCR was performed to determine miR-26b expression in obese rodent models, human obesity subjects and insulin-resistant adipocytes. We analysed the roles of miR-26b overexpression and inhibition on glucose uptake in adipocytes. Western blotting was used to detect the levels of protein molecules involved in the phosphoinositide-3-kinase (PI3K) pathway. Bioinformatics and the Dual Luciferase Assay were used to identify the target gene of miR-26b. We assessed the regulatory roles of miR-26b on the phosphatase and tensin homologue (PTEN)/PI3K/AKT pathway and the relationship between miR-26b and the metabolism of human obese subjects. RESULTS Levels of miR-26b are reduced in visceral adipose tissue (VAT) in obese rodent models, human obesity and insulin-resistant adipocytes. MiR-26b promotes insulin-stimulated glucose uptake and increases insulin-stimulated glucose transporter type 4 translocation to the plasma membrane in human mature adipocytes. MiR-26b modulates insulin-stimulated AKT activation via inhibition of its target gene, PTEN, and significantly increases insulin sensitivity via the PTEN/PI3K/AKT pathway. The expression level of miR-26b negatively correlates with increasing body mass index and homeostasis model assessment for IR in human obese subjects. CONCLUSION Decreased miR-26b expression in VAT may be involved in obesity-related IR by interrupting the PTEN/PI3K/AKT pathway.
Collapse
|
258
|
Huang F, Lu MH, Gong HY, Xiong ZP. Changes in peripheral blood natural killer T cells in hepatitis B e antigen-positive chronic hepatitis B patients and efficacy prediction after pegylated interferon therapy. GENETICS AND MOLECULAR RESEARCH 2015; 14:4932-8. [PMID: 25966268 DOI: 10.4238/2015.may.11.26] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
We examined the expression of peripheral blood natural killer T (NKT) cells in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) patients and predicted its efficacy after pegylated interferon α-2a (Peg-INFα-2a) therapy. Sixty-three cases of HbeAg-positive CHB inpatients and outpatients, treated in the Third Xiangya Hospital of Central South University from January to December 2010, were administrated Peg-INFα-2a 18 myriad international unit intramuscularly once per week for 48 weeks. The number of peripheral NKT cells, 5 quantitative indicators of hepatitis B, and hepatitis B virus DNA capacity were detected at each time point. Forty-eight weeks after Peg-INFα-2a treatment, 26 HBeAg-positive CHB patients exhibited significant effects, 21 cases exhibited effects, and 16 cases showed no effects. The ratio of peripheral blood NKT cells in T lymphocytes before and 4, 8, and 12 weeks after treatment in the significant effect group was significantly increased compared to the effect group and no effect group (P < 0.01); at the 48th week of treatment and 24 weeks after the drug was withdrawn, NKT cell expression in the significant effect group was significantly higher than that in the effect group (t = 32.0, P < 0.01; t = 27.6, P < 0.01, respectively). A total of 27 patients showed HBeAg seroconversion until the 24th week after drug withdrawal. During treatment with Peg-INFα-2a in HBeAg-positive CHB patients, expression of peripheral blood NKT cells could be used to predict efficacy.
Collapse
|
259
|
Aartsen MG, Ackermann M, Adams J, Aguilar JA, Ahlers M, Ahrens M, Altmann D, Anderson T, Arguelles C, Arlen TC, Auffenberg J, Bai X, Barwick SW, Baum V, Bay R, Beatty JJ, Becker Tjus J, Becker KH, BenZvi S, Berghaus P, Berley D, Bernardini E, Bernhard A, Besson DZ, Binder G, Bindig D, Bissok M, Blaufuss E, Blumenthal J, Boersma DJ, Bohm C, Bos F, Bose D, Böser S, Botner O, Brayeur L, Bretz HP, Brown AM, Buzinsky N, Casey J, Casier M, Cheung E, Chirkin D, Christov A, Christy B, Clark K, Classen L, Clevermann F, Coenders S, Cowen DF, Cruz Silva AH, Daughhetee J, Davis JC, Day M, de André JPAM, De Clercq C, Dembinski H, De Ridder S, Desiati P, de Vries KD, de With M, DeYoung T, Díaz-Vélez JC, Dumm JP, Dunkman M, Eagan R, Eberhardt B, Ehrhardt T, Eichmann B, Eisch J, Euler S, Evenson PA, Fadiran O, Fazely AR, Fedynitch A, Feintzeig J, Felde J, Filimonov K, Finley C, Fischer-Wasels T, Flis S, Frantzen K, Fuchs T, Gaisser TK, Gaior R, Gallagher J, Gerhardt L, Gier D, Gladstone L, Glüsenkamp T, Goldschmidt A, Golup G, Gonzalez JG, Goodman JA, Góra D, Grant D, Gretskov P, Groh JC, Groß A, Ha C, Haack C, Haj Ismail A, Hallen P, Hallgren A, Halzen F, Hanson K, Hebecker D, Heereman D, Heinen D, Helbing K, Hellauer R, Hellwig D, Hickford S, Hill GC, Hoffman KD, Hoffmann R, Homeier A, Hoshina K, Huang F, Huelsnitz W, Hulth PO, Hultqvist K, Ishihara A, Jacobi E, Jacobsen J, Japaridze GS, Jero K, Jurkovic M, Kaminsky B, Kappes A, Karg T, Karle A, Kauer M, Keivani A, Kelley JL, Kheirandish A, Kiryluk J, Kläs J, Klein SR, Köhne JH, Kohnen G, Kolanoski H, Koob A, Köpke L, Kopper C, Kopper S, Koskinen DJ, Kowalski M, Kriesten A, Krings K, Kroll G, Kroll M, Kunnen J, Kurahashi N, Kuwabara T, Labare M, Lanfranchi JL, Larsen DT, Larson MJ, Lesiak-Bzdak M, Leuermann M, Lünemann J, Madsen J, Maggi G, Maruyama R, Mase K, Matis HS, Maunu R, McNally F, Meagher K, Medici M, Meli A, Meures T, Miarecki S, Middell E, Middlemas E, Milke N, Miller J, Mohrmann L, Montaruli T, Morse R, Nahnhauer R, Naumann U, Niederhausen H, Nowicki SC, Nygren DR, Obertacke A, Olivas A, Omairat A, O'Murchadha A, Palczewski T, Paul L, Penek Ö, Pepper JA, Pérez de los Heros C, Pfendner C, Pieloth D, Pinat E, Posselt J, Price PB, Przybylski GT, Pütz J, Quinnan M, Rädel L, Rameez M, Rawlins K, Redl P, Rees I, Reimann R, Relich M, Resconi E, Rhode W, Richman M, Riedel B, Robertson S, Rodrigues JP, Rongen M, Rott C, Ruhe T, Ruzybayev B, Ryckbosch D, Saba SM, Sander HG, Sandroos J, Santander M, Sarkar S, Schatto K, Scheriau F, Schmidt T, Schmitz M, Schoenen S, Schöneberg S, Schönwald A, Schukraft A, Schulte L, Schulz O, Seckel D, Sestayo Y, Seunarine S, Shanidze R, Smith MWE, Soldin D, Spiczak GM, Spiering C, Stamatikos M, Stanev T, Stanisha NA, Stasik A, Stezelberger T, Stokstad RG, Stößl A, Strahler EA, Ström R, Strotjohann NL, Sullivan GW, Taavola H, Taboada I, Tamburro A, Ter-Antonyan S, Terliuk A, Tešić G, Tilav S, Toale PA, Tobin MN, Tosi D, Tselengidou M, Unger E, Usner M, Vallecorsa S, van Eijndhoven N, Vandenbroucke J, van Santen J, Vanheule S, Vehring M, Voge M, Vraeghe M, Walck C, Wallraff M, Weaver C, Wellons M, Wendt C, Westerhoff S, Whelan BJ, Whitehorn N, Wichary C, Wiebe K, Wiebusch CH, Williams DR, Wissing H, Wolf M, Wood TR, Woschnagg K, Xu DL, Xu XW, Xu Y, Yanez JP, Yodh G, Yoshida S, Zarzhitsky P, Ziemann J, Zoll M. Flavor Ratio of Astrophysical Neutrinos above 35 TeV in IceCube. PHYSICAL REVIEW LETTERS 2015; 114:171102. [PMID: 25978221 DOI: 10.1103/physrevlett.114.171102] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2015] [Indexed: 06/04/2023]
Abstract
A diffuse flux of astrophysical neutrinos above 100 TeV has been observed at the IceCube Neutrino Observatory. Here we extend this analysis to probe the astrophysical flux down to 35 TeV and analyze its flavor composition by classifying events as showers or tracks. Taking advantage of lower atmospheric backgrounds for showerlike events, we obtain a shower-biased sample containing 129 showers and 8 tracks collected in three years from 2010 to 2013. We demonstrate consistency with the (fe:fμ:fτ)⊕≈(1:1:1)⊕ flavor ratio at Earth commonly expected from the averaged oscillations of neutrinos produced by pion decay in distant astrophysical sources. Limits are placed on nonstandard flavor compositions that cannot be produced by averaged neutrino oscillations but could arise in exotic physics scenarios. A maximally tracklike composition of (0:1:0)⊕ is excluded at 3.3σ, and a purely showerlike composition of (1:0:0)⊕ is excluded at 2.3σ.
Collapse
|
260
|
Xu C, Ju X, Song D, Huang F, Tang D, Zou Z, Zhang C, Joshi T, Jia L, Xu W, Xu KF, Wang Q, Xiong Y, Guo Z, Chen X, Huang F, Xu J, Zhong Y, Zhu Y, Peng Y, Wang L, Zhang X, Jiang R, Li D, Jiang T, Xu D, Jiang C. An association analysis between psychophysical characteristics and genome-wide gene expression changes in human adaptation to the extreme climate at the Antarctic Dome Argus. Mol Psychiatry 2015; 20:536-44. [PMID: 25199918 DOI: 10.1038/mp.2014.72] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2013] [Revised: 05/26/2014] [Accepted: 06/05/2014] [Indexed: 11/09/2022]
Abstract
Genome-wide gene expression measurements have enabled comprehensive studies that integrate the changes of gene expression and phenotypic information to uncover their novel associations. Here we reported the association analysis between psychophysical phenotypes and genome-wide gene expression changes in human adaptation to one of the most extreme climates on Earth, the Antarctic Dome Argus. Dome A is the highest ice feature in Antarctica, and may be the coldest, driest and windiest location on earth. It is considered unapproachable due to its hostile environment. In 2007, a Chinese team of 17 male explorers made the expedition to Dome A for scientific investigation. Overall, 133 psychophysical phenotypes were recorded, and genome-wide gene expression profiles from the blood samples of the explorers were measured before their departure and upon their arrival at Dome A. We found that mood disturbances, including tension (anxiety), depression, anger and fatigue, had a strong, positive, linear relationship with the level of a male sex hormone, testosterone, using the Pearson correlation coefficient (PCC) analysis. We also demonstrated that significantly lowest-level Gene Ontology groups in changes of gene expression in blood cells with erythrocyte removal were consistent with the adaptation of the psychophysical characteristics. Interestingly, we discovered a list of genes that were strongly related to significant phenotypes using phenotype and gene expression PCC analysis. Importantly, among the 70 genes that were identified, most were significantly related to mood disturbances, where 42 genes have been reported in the literature mining, suggesting that the other 28 genes were likely novel genes involved in the mood disturbance mechanism. Taken together, our association analysis provides a reliable method to uncover novel genes and mechanisms related to phenotypes, although further studies are needed.
Collapse
|
261
|
Fan W, Zhu X, Wu L, Wu Z, Li D, Huang F, He H. Propofol: an anesthetic possessing neuroprotective effects. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2015; 19:1520-1529. [PMID: 25967729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Propofol is a short-acting intravenous anaesthetic agent and widely used not only in operating rooms but also in the intensive care unit (ICU). Apart from its multiple anaesthetic advantages, the neuroprotective effect of propofol has been demonstrated in diverse models of neuronal injury. The effect of propofol results from activation of gamma-aminobutyric acid (GABA) receptor, modulation excitatory amino acid transmitter system and protecting brain cells against oxidative stress. Moreover, propofol is able to supress apoptosis and inflammation and to regulate neuroprotection-associated proteins or ion homeostasis to act its neuroprotective effects. This review focuses on the research progress of the neuroprotective effects of propofol and its mechanisms of action to date. The implications for possible use for the clinical setting are also discussed.
Collapse
|
262
|
Chisti A, Gupta M, Rosenberg I, Wang J, Craycroft J, Gutierrez D, Bhatt A, Huang F. Launching an interactive cancer projects map: A collaborative approach to
global cancer research and program development. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
263
|
Vallurupalli M, Shulman D, Elmore S, Xu M, Dolisca S, Ilcisin L, Judd A, Kolarova T, Lock J, Niu N, Olsen M, Taylor K, Holmer H, Bhatt A, Huang F. Students for global oncology: Building a movement for student education
and engagement in an emerging field. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
264
|
Sullivan B, Bhatt A, Huang F, Atun R, Maruthappu M, Fitchett J, Head M. US and UK investments in global oncology research: A systematic
analysis. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
265
|
Kazberouk A, Mychko O, Slater S, Doyle K, Skoniecki D, Kamdar M, Soldak T, Bhatt A, Huang F. Palliative care education in Belarus: Development and delivery of a
cost-efficient, streamlined and targeted palliative care curriculum. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
266
|
Olsen M, Manzo V, Cardenas C, Bhatt A, Fajardo A, Huang F, Jacobs M, Kennell-Heiling S, May L, Mehrtash H, Taylor K, Xu M. Creating and implementing low literacy cancer education materials:
bridging the gap in sub-Saharan Africa. Ann Glob Health 2015. [DOI: 10.1016/j.aogh.2015.02.984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
267
|
Aartsen MG, Ackermann M, Adams J, Aguilar JA, Ahlers M, Ahrens M, Altmann D, Anderson T, Arguelles C, Arlen TC, Auffenberg J, Bai X, Barwick SW, Baum V, Beatty JJ, Tjus JB, Becker KH, BenZvi S, Berghaus P, Berley D, Bernardini E, Bernhard A, Besson DZ, Binder G, Bindig D, Bissok M, Blaufuss E, Blumenthal J, Boersma DJ, Bohm C, Bos F, Bose D, Böser S, Botner O, Brayeur L, Bretz HP, Brown AM, Casey J, Casier M, Cheung E, Chirkin D, Christov A, Christy B, Clark K, Classen L, Clevermann F, Coenders S, Cowen DF, Cruz Silva AH, Danninger M, Daughhetee J, Davis JC, Day M, de André JPAM, De Clercq C, De Ridder S, Desiati P, de Vries KD, de With M, DeYoung T, Díaz-Vélez JC, Dunkman M, Eagan R, Eberhardt B, Eichmann B, Eisch J, Euler S, Evenson PA, Fadiran O, Fazely AR, Fedynitch A, Feintzeig J, Felde J, Feusels T, Filimonov K, Finley C, Fischer-Wasels T, Flis S, Franckowiak A, Frantzen K, Fuchs T, Gaisser TK, Gaior R, Gallagher J, Gerhardt L, Gier D, Gladstone L, Glüsenkamp T, Goldschmidt A, Golup G, Gonzalez JG, Goodman JA, Góra D, Grant D, Gretskov P, Groh JC, Groß A, Ha C, Haack C, Haj Ismail A, Hallen P, Hallgren A, Halzen F, Hanson K, Hebecker D, Heereman D, Heinen D, Helbing K, Hellauer R, Hellwig D, Hickford S, Hill GC, Hoffman KD, Hoffmann R, Homeier A, Hoshina K, Huang F, Huelsnitz W, Hulth PO, Hultqvist K, Hussain S, Ishihara A, Jacobi E, Jacobsen J, Jagielski K, Japaridze GS, Jero K, Jlelati O, Jurkovic M, Kaminsky B, Kappes A, Karg T, Karle A, Kauer M, Keivani A, Kelley JL, Kheirandish A, Kiryluk J, Kläs J, Klein SR, Köhne JH, Kohnen G, Kolanoski H, Koob A, Köpke L, Kopper C, Kopper S, Koskinen DJ, Kowalski M, Kriesten A, Krings K, Kroll G, Kroll M, Kunnen J, Kurahashi N, Kuwabara T, Labare M, Larsen DT, Larson MJ, Lesiak-Bzdak M, Leuermann M, Leute J, Lünemann J, Madsen J, Maggi G, Maruyama R, Mase K, Matis HS, Maunu R, McNally F, Meagher K, Medici M, Meli A, Meures T, Miarecki S, Middell E, Middlemas E, Milke N, Miller J, Mohrmann L, Montaruli T, Morse R, Nahnhauer R, Naumann U, Niederhausen H, Nowicki SC, Nygren DR, Obertacke A, Odrowski S, Olivas A, Omairat A, O’Murchadha A, Palczewski T, Paul L, Penek Ö, Pepper JA, Pérez de los Heros C, Pfendner C, Pieloth D, Pinat E, Posselt J, Price PB, Przybylski GT, Pütz J, Quinnan M, Rädel L, Rameez M, Rawlins K, Redl P, Rees I, Reimann R, Relich M, Resconi E, Rhode W, Richman M, Riedel B, Robertson S, Rodrigues JP, Rongen M, Rott C, Ruhe T, Ruzybayev B, Ryckbosch D, Saba SM, Sander HG, Sandroos J, Santander M, Sarkar S, Schatto K, Scheriau F, Schmidt T, Schmitz M, Schoenen S, Schöneberg S, Schönwald A, Schukraft A, Schulte L, Schulz O, Seckel D, Sestayo Y, Seunarine S, Shanidze R, Smith MWE, Soldin D, Spiczak GM, Spiering C, Stamatikos M, Stanev T, Stanisha NA, Stasik A, Stezelberger T, Stokstad RG, Stößl A, Strahler EA, Ström R, Strotjohann NL, Sullivan GW, Taavola H, Taboada I, Tamburro A, Tepe A, Ter-Antonyan S, Terliuk A, Tešić G, Tilav S, Toale PA, Tobin MN, Tosi D, Tselengidou M, Unger E, Usner M, Vallecorsa S, van Eijndhoven N, Vandenbroucke J, van Santen J, Vehring M, Voge M, Vraeghe M, Walck C, Wallraff M, Weaver C, Wellons M, Wendt C, Westerhoff S, Whelan BJ, Whitehorn N, Wichary C, Wiebe K, Wiebusch CH, Williams DR, Wissing H, Wolf M, Wood TR, Woschnagg K, Xu DL, Xu XW, Yanez JP, Yodh G, Yoshida S, Zarzhitsky P, Ziemann J, Zierke S, Zoll M, Morik K. Development of a general analysis and unfolding scheme and its application to measure the energy spectrum of atmospheric neutrinos with IceCube: IceCube Collaboration. THE EUROPEAN PHYSICAL JOURNAL. C, PARTICLES AND FIELDS 2015; 75:116. [PMID: 25995705 PMCID: PMC4429507 DOI: 10.1140/epjc/s10052-015-3330-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/15/2014] [Accepted: 02/19/2015] [Indexed: 06/04/2023]
Abstract
We present the development and application of a generic analysis scheme for the measurement of neutrino spectra with the IceCube detector. This scheme is based on regularized unfolding, preceded by an event selection which uses a Minimum Redundancy Maximum Relevance algorithm to select the relevant variables and a random forest for the classification of events. The analysis has been developed using IceCube data from the 59-string configuration of the detector. 27,771 neutrino candidates were detected in 346 days of livetime. A rejection of 99.9999 % of the atmospheric muon background is achieved. The energy spectrum of the atmospheric neutrino flux is obtained using the TRUEE unfolding program. The unfolded spectrum of atmospheric muon neutrinos covers an energy range from 100 GeV to 1 PeV. Compared to the previous measurement using the detector in the 40-string configuration, the analysis presented here, extends the upper end of the atmospheric neutrino spectrum by more than a factor of two, reaching an energy region that has not been previously accessed by spectral measurements.
Collapse
|
268
|
Li DJ, Huang F, Lu WJ, Jiang GJ, Deng YP, Shen FM. Metformin promotes irisin release from murine skeletal muscle independently of AMP-activated protein kinase activation. Acta Physiol (Oxf) 2015; 213:711-21. [PMID: 25382002 DOI: 10.1111/apha.12421] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2014] [Revised: 09/01/2014] [Accepted: 11/05/2014] [Indexed: 12/25/2022]
Abstract
AIM Irisin, a novel myocyte-secreted hormone mediating beneficial effects of exercise on metabolism, is supposed to be an ideal therapeutic target for metabolic disorders such as obesity and diabetes. Here, we investigated the potential effects of metformin and glibenclamide, two antidiabetic medicines, on irisin release in mouse. METHODS Wild-type and diabetic obese db/db mice were administrated with metformin and glibenclamide for 2 weeks, and cultured C2C12 myotubes were treated by metformin. Expression of irisin precursor FNDC5 was measured and blood irisin concentration was detected. AMP-activated protein kinase (AMPK) was blocked by chemical inhibitor compound C or knocking down with specific siRNA. RESULTS The mRNA and protein expression of FNDC5 in skeletal muscle and blood irisin concentrations were lower in diabetic db/db mice than those in wild-type mice. Metformin and glibenclamide decreased blood glucose in db/db mice. Metformin, but not glibenclamide, increased intramuscular FNDC5 mRNA/protein expression and blood irisin levels. Additionally, the reductions of blood glucose and body weight in metformin-treated db/db mice were positively associated with blood irisin concentrations. In C2C12 myotubes, metformin upregulated intracellular FDNC5 mRNA/protein expression and promoted irisin release. Although metformin activated AMPK signalling in skeletal muscle cells, disrupting of AMPK signalling by chemical inhibitor or siRNA-mediated knockdown did not abolish the promoting effect of metformin on irisin release. CONCLUSION Metformin promotes irisin release from murine skeletal muscle into blood, independently of AMPK pathway activation. Our results suggest that stimulation of irisin may be a novel molecular mechanism of metformin which is widely used for treatment of metabolic disorders.
Collapse
|
269
|
Yang C, Shang J, Zheng H, Chen M, Huang F, Li C, Yang B, Liang X. 25 DEVELOPMENTAL COMPETENCE OF CLONED BUFFALO (BUBALUS BUBALIS) EMBRYOS PRODUCED BY TRANSFECTED OR NONTRANSFECTED FIBROBLASTS TRANSFER TO ENUCLEATED OOCYTES DERIVED FROM OVUM PICK-UP AND ABATTOIR OVARIES. Reprod Fertil Dev 2015. [DOI: 10.1071/rdv27n1ab25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The objective of this study was to explore whether fibroblasts transfection and the source of oocytes – ovum pick-up (OPU) versus abattoir ovaries – affected the in vitro and in vivo developmental competence of somatic cell nuclear transferred (SCNT) embryos in buffalo. To this aim, the serum-starved ear fibroblasts were fused into enucleated oocytes derived from abattoir ovaries (Group 1) and OPU (Group 2). Furthermore, the enucleated buffalo oocytes derived from abattoir ovaries were also fused with pEGFP-N1 transfected ear fibroblasts, and the cloned embryos were enhanced green fluorescent protein (EGFP)-positive confirmed by fluorescence microscopy (Group 3). The reconstructed embryos cultured in Groups 1 to 3 were 262, 83, 120, respectively (5 replicates); and the data were analysed by one-way ANOVA (SPSS Inc., Chicago, IL, USA). As a result, the cleavage rate in Group 3 was significantly higher than that in Group 1 (75.0% v. 54.3%; P < 0.01), and the total blastocyst rate of reconstructed embryos in Group 3 (27.3%) was significantly higher than that in Group 1 (17.4%; P < 0.01) and Group 2 (24.4%; P < 0.05). The SCNT blastocysts were vitrified with 20% ethylene glycol + 20% dimethylsulfoxide + 0.5 M sucrose; the cryosurvival rates of SCNT blastocysts in the 3 groups were not different from each other (90.0%, 94.7%, 92.3%). Following culture, the cryosurvived blastocysts were transferred into synchronized local and crossbred buffaloes, with each recipient receiving 1 or 2 embryos. The pregnancy rates after transferring embryos derived from Groups 1 to 3 were not different from each other, and were 18.75% (3/16), 33.33% (4/12), and 26.67% (4/15), respectively. These results indicate that the oocytes derived from OPU can be enucleated as recipient cytoplasm and transfected fibroblast can be adopted as nuclei donor without decreasing the SCNT efficiency in buffalo.This research was supported by grants from the National Natural Science Foundation of China (31160456) and the Natural Science Foundations of China under Grant No. 0991011, No. 2011GXSFB018045).
Collapse
|
270
|
Huang F, Moschetti V, Lang B, Halabi A, Petersen-Sylla M, Yong CL, Elgadi M. Pharmacokinetics, safety, and tolerability of faldaprevir in patients with renal impairment. Antimicrob Agents Chemother 2015; 59:251-7. [PMID: 25348520 PMCID: PMC4291359 DOI: 10.1128/aac.03359-14] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2014] [Accepted: 10/18/2014] [Indexed: 02/06/2023] Open
Abstract
Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor with negligible urinary excretion. We assessed the pharmacokinetics and safety of a single oral dose of faldaprevir (480 mg) in 32 HCV-negative subjects with renal impairment or normal renal function. Compared with subjects with normal renal function, the adjusted geometric mean ratios (90% confidence intervals in parentheses) for overall exposure area under the concentration-time curve from zero to infinity (AUC0-∞) were 113.6% (41.6 to 310.2%), 178.3% (85.2 to 373.0%), and 169.2% (73.2 to 391.2%) for subjects with mild, moderate, and severe renal impairment, respectively. Overall, 5/8 (63%) subjects with normal renal function and 20/24 (83%) subjects with renal impairment reported adverse events, with gastrointestinal events being the most common. No severe or serious adverse events or deaths were reported. These results suggest that moderate or severe renal impairment can result in a modest increase in faldaprevir exposure. The increase in exposure may be related to decrease in the activity of the liver uptake transporter OATP1B1 as a result of renal impairment. Given this relatively slight increase in exposure, a dose adjustment in HCV patients with renal impairment is not warranted. (This study has been registered at ClinicalTrials.gov under registration number NCT01957657.).
Collapse
|
271
|
Sabo JP, Lang B, Elgadi M, Huang F. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers. Antimicrob Agents Chemother 2015; 59:514-9. [PMID: 25385099 PMCID: PMC4291440 DOI: 10.1128/aac.03589-14] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Accepted: 10/31/2014] [Indexed: 01/13/2023] Open
Abstract
Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor. Faldaprevir is known to inhibit P-glycoprotein, CYP3A4, and UDP-glucuronosyltransferase 1A1. This study evaluated the effect of steady-state 240 mg faldaprevir on the pharmacokinetics (PK) of an oral contraceptive containing ethinylestradiol (EE) and levonorgestrel (LNG) in healthy premenopausal women. In period 1, subjects received EE/LNG once daily (QD) for 14 days. Blood samples were taken on days 1, 11, and 12, with intensive PK blood sampling for EE and LNG on day 13. In period 2, subjects received EE-LNG QD and 240 mg faldaprevir QD on days 14 to 21 (240 mg faldaprevir twice daily on day 14). Blood samples were taken on days 14, 19, and 20, with PK profiling samples obtained for EE and LNG on day 21. A total of 15/16 subjects completed the study. Overall, EE and LNG exposure (assessed by the area under the curve) was approximately 1.4-fold higher when EE and LNG were coadministered with faldaprevir than when administered alone. Median t1/2 (terminal half-life in plasma at steady state) values were prolonged for both EE (2.4 h longer) and LNG (4.7 h longer) when EE and LNG were coadministered with faldaprevir. The mean oral clearance and apparent volume of distribution of both EE and LNG were lower (∼ 30%) when EE and LNG were coadministered with faldaprevir. Coadministration of faldaprevir and an oral contraceptive resulted in a moderate increase in exposure to both EE and LNG. However, this increase was not considered clinically meaningful, and no dose adjustment of oral contraceptives was deemed necessary. (This study has been registered at ClinicalTrials.gov under registration number NCT01570244.).
Collapse
|
272
|
Joseph D, Rose P, Strelkowa N, Schultz A, Garcia J, Elgadi M, Huang F. Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers. J Clin Pharmacol 2014; 55:384-91. [PMID: 25352040 DOI: 10.1002/jcph.418] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 10/20/2014] [Indexed: 12/21/2022]
Abstract
Faldaprevir is a potent hepatitis C virus (HCV) NS3/4A protease inhibitor and an inhibitor of UDP-glucuronosyltransferase-1A1 (UGT1A1), which is involved in raltegravir clearance. Raltegravir, an HIV integrase inhibitor, may be used in combination with HCV treatment in HCV/HIV co-infected patients. In this open-label, 2-period, fixed-sequence study, 24 healthy volunteers (12 males) received faldaprevir 240 mg and raltegravir 400 mg in 2 treatment schedules (A and B) separated by a washout phase of ≥7 days: (A) twice-daily raltegravir (Days 1-3), once-daily raltegravir (Day 4); (B) twice-daily raltegravir and twice-daily faldaprevir (loading dose, Day 1), twice-daily raltegravir and once-daily faldaprevir (Days 2-5), once-daily raltegravir and once-daily faldaprevir (Day 6). Pharmacokinetics and safety were assessed over 132 hours post-dosing. Compared with raltegravir alone, co-administration with faldaprevir led to 2.7-fold and 2.5-fold increases in raltegravir geometric mean AUC(τ,ss) and C(max,ss), respectively, and a similar increase in raltegravir glucuronide metabolite exposure. No serious adverse events (AEs) were reported and no subject discontinued due to AEs. Faldaprevir and raltegravir co-administration was well tolerated and resulted in a moderate increase in raltegravir exposure.
Collapse
|
273
|
Zhou T, Liu L, Goddard WA, Zybin SV, Huang F. ReaxFF reactive molecular dynamics on silicon pentaerythritol tetranitrate crystal validates the mechanism for the colossal sensitivity. Phys Chem Chem Phys 2014; 16:23779-91. [PMID: 25272955 DOI: 10.1039/c4cp03781b] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
274
|
Wang M, Gao XJ, Zhao WW, Zhao WJ, Jiang CH, Huang F, Kou JP, Liu BL, Liu K. Opposite effects of genistein on the regulation of insulin-mediated glucose homeostasis in adipose tissue. Br J Pharmacol 2014; 170:328-40. [PMID: 23763311 DOI: 10.1111/bph.12276] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Revised: 05/23/2013] [Accepted: 05/31/2013] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND AND PURPOSE Genistein is an isoflavone phytoestrogen found in a number of plants such as soybeans and there is accumulating evidence that it has beneficial effects on the regulation of glucose homeostasis. In this study we evaluated the effect of genistein on glucose homeostasis and its underlying mechanisms in normal and insulin-resistant conditions. EXPERIMENTAL APPROACH To induce insulin resistance, mice or differentiated 3T3-L1 adipocytes were treated with macrophage-derived conditioned medium. A glucose tolerance test was used to investigate the effect of genistein. Insulin signalling activation, glucose transporter-4 (GLUT4) translocation and AMP-activated PK (AMPK) activation were detected by Western blot analysis or elisa. KEY RESULTS Genistein impaired glucose tolerance and attenuated insulin sensitivity in normal mice by inhibiting the insulin-induced phosphorylation of insulin receptor substrate-1 (IRS1) at tyrosine residues, leading to inhibition of insulin-mediated GLUT4 translocation in adipocytes. Mac-CM, an inflammatory stimulus induced glucose intolerance accompanied by impaired insulin sensitivity; genistein reversed these changes by restoring the disturbed IRS1 function, leading to an improvement in GLUT4 translocation. In addition, genistein increased AMPK activity under both normal and inflammatory conditions; this was shown to contribute to the anti-inflammatory effect of genistein, which leads to an improvement in insulin signalling and the amelioration of insulin resistance. CONCLUSION AND IMPLICATIONS Genistein showed opposite effects on insulin sensitivity under normal and inflammatory conditions in adipose tissue and this action was derived from its negative or positive regulation of IRS1 function. Its up-regulation of AMPK activity contributes to the inhibition of inflammation implicated in insulin resistance.
Collapse
|
275
|
Aartsen MG, Ackermann M, Adams J, Aguilar JA, Ahlers M, Ahrens M, Altmann D, Anderson T, Arguelles C, Arlen TC, Auffenberg J, Bai X, Barwick SW, Baum V, Beatty JJ, Becker Tjus J, Becker KH, BenZvi S, Berghaus P, Berley D, Bernardini E, Bernhard A, Besson DZ, Binder G, Bindig D, Bissok M, Blaufuss E, Blumenthal J, Boersma DJ, Bohm C, Bose D, Böser S, Botner O, Brayeur L, Bretz HP, Brown AM, Casey J, Casier M, Chirkin D, Christov A, Christy B, Clark K, Classen L, Clevermann F, Coenders S, Cowen DF, Cruz Silva AH, Danninger M, Daughhetee J, Davis JC, Day M, de André JPAM, De Clercq C, De Ridder S, Desiati P, de Vries KD, de With M, DeYoung T, Díaz-Vélez JC, Dunkman M, Eagan R, Eberhardt B, Eichmann B, Eisch J, Euler S, Evenson PA, Fadiran O, Fazely AR, Fedynitch A, Feintzeig J, Felde J, Feusels T, Filimonov K, Finley C, Fischer-Wasels T, Flis S, Franckowiak A, Frantzen K, Fuchs T, Gaisser TK, Gallagher J, Gerhardt L, Gier D, Gladstone L, Glüsenkamp T, Goldschmidt A, Golup G, Gonzalez JG, Goodman JA, Góra D, Grandmont DT, Grant D, Gretskov P, Groh JC, Groß A, Ha C, Haack C, Haj Ismail A, Hallen P, Hallgren A, Halzen F, Hanson K, Hebecker D, Heereman D, Heinen D, Helbing K, Hellauer R, Hellwig D, Hickford S, Hill GC, Hoffman KD, Hoffmann R, Homeier A, Hoshina K, Huang F, Huelsnitz W, Hulth PO, Hultqvist K, Hussain S, Ishihara A, Jacobi E, Jacobsen J, Jagielski K, Japaridze GS, Jero K, Jlelati O, Jurkovic M, Kaminsky B, Kappes A, Karg T, Karle A, Kauer M, Kelley JL, Kheirandish A, Kiryluk J, Kläs J, Klein SR, Köhne JH, Kohnen G, Kolanoski H, Koob A, Köpke L, Kopper C, Kopper S, Koskinen DJ, Kowalski M, Kriesten A, Krings K, Kroll G, Kunnen J, Kurahashi N, Kuwabara T, Labare M, Larsen DT, Larson MJ, Lesiak-Bzdak M, Leuermann M, Leute J, Lünemann J, Macías O, Madsen J, Maggi G, Maruyama R, Mase K, Matis HS, McNally F, Meagher K, Meli A, Meures T, Miarecki S, Middell E, Middlemas E, Milke N, Miller J, Mohrmann L, Montaruli T, Morse R, Nahnhauer R, Naumann U, Niederhausen H, Nowicki SC, Nygren DR, Obertacke A, Odrowski S, Olivas A, Omairat A, O'Murchadha A, Palczewski T, Paul L, Penek O, Pepper JA, Pérez de Los Heros C, Pfendner C, Pieloth D, Pinat E, Posselt J, Price PB, Przybylski GT, Pütz J, Quinnan M, Rädel L, Rameez M, Rawlins K, Redl P, Rees I, Reimann R, Resconi E, Rhode W, Richman M, Riedel B, Robertson S, Rodrigues JP, Rongen M, Rott C, Ruhe T, Ruzybayev B, Ryckbosch D, Saba SM, Sander HG, Santander M, Sarkar S, Schatto K, Scheriau F, Schmidt T, Schmitz M, Schoenen S, Schöneberg S, Schönwald A, Schukraft A, Schulte L, Schulz O, Seckel D, Sestayo Y, Seunarine S, Shanidze R, Sheremata C, Smith MWE, Soldin D, Spiczak GM, Spiering C, Stamatikos M, Stanev T, Stanisha NA, Stasik A, Stezelberger T, Stokstad RG, Stößl A, Strahler EA, Ström R, Strotjohann NL, Sullivan GW, Taavola H, Taboada I, Tamburro A, Tepe A, Ter-Antonyan S, Terliuk A, Tešić G, Tilav S, Toale PA, Tobin MN, Tosi D, Tselengidou M, Unger E, Usner M, Vallecorsa S, van Eijndhoven N, Vandenbroucke J, van Santen J, Vehring M, Voge M, Vraeghe M, Walck C, Wallraff M, Weaver C, Wellons M, Wendt C, Westerhoff S, Whelan BJ, Whitehorn N, Wichary C, Wiebe K, Wiebusch CH, Williams DR, Wissing H, Wolf M, Wood TR, Woschnagg K, Xu DL, Xu XW, Yanez JP, Yodh G, Yoshida S, Zarzhitsky P, Ziemann J, Zierke S, Zoll M. Observation of high-energy astrophysical neutrinos in three years of IceCube data. PHYSICAL REVIEW LETTERS 2014; 113:101101. [PMID: 25238345 DOI: 10.1103/physrevlett.113.101101] [Citation(s) in RCA: 150] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/21/2014] [Indexed: 06/03/2023]
Abstract
A search for high-energy neutrinos interacting within the IceCube detector between 2010 and 2012 provided the first evidence for a high-energy neutrino flux of extraterrestrial origin. Results from an analysis using the same methods with a third year (2012-2013) of data from the complete IceCube detector are consistent with the previously reported astrophysical flux in the 100 TeV-PeV range at the level of 10(-8) GeV cm-2 s-1 sr-1 per flavor and reject a purely atmospheric explanation for the combined three-year data at 5.7σ. The data are consistent with expectations for equal fluxes of all three neutrino flavors and with isotropic arrival directions, suggesting either numerous or spatially extended sources. The three-year data set, with a live time of 988 days, contains a total of 37 neutrino candidate events with deposited energies ranging from 30 to 2000 TeV. The 2000-TeV event is the highest-energy neutrino interaction ever observed.
Collapse
|